Alessia Bottos

935 total citations
37 papers, 602 citations indexed

About

Alessia Bottos is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Alessia Bottos has authored 37 papers receiving a total of 602 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pathology and Forensic Medicine, 19 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Alessia Bottos's work include Lymphoma Diagnosis and Treatment (25 papers), CAR-T cell therapy research (15 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Alessia Bottos is often cited by papers focused on Lymphoma Diagnosis and Treatment (25 papers), CAR-T cell therapy research (15 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Alessia Bottos collaborates with scholars based in Switzerland, United Kingdom and United States. Alessia Bottos's co-authors include Federico Bussolino, Marco Arese, Alberto Rissone, Nancy E. Hynes, Alberto Bardelli, Aleksandra Wodnar‐Filipowicz, Stefania Bruno, Giuliana Cavalloni, Manuela Motta and Franca Fagioli and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Alessia Bottos

32 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alessia Bottos Switzerland 12 284 238 142 112 91 37 602
Fiona Chionh Australia 15 393 1.4× 344 1.4× 191 1.3× 152 1.4× 95 1.0× 26 839
Julie Godet France 16 196 0.7× 253 1.1× 86 0.6× 161 1.4× 57 0.6× 26 563
Muayad F. Almahariq United States 12 125 0.4× 268 1.1× 103 0.7× 77 0.7× 50 0.5× 33 616
Gina Lama Italy 17 197 0.7× 286 1.2× 256 1.8× 187 1.7× 158 1.7× 27 931
Nataliya V. Uboha United States 15 326 1.1× 182 0.8× 49 0.3× 143 1.3× 70 0.8× 69 588
Yolanda Ruano Spain 13 147 0.5× 314 1.3× 55 0.4× 111 1.0× 77 0.8× 40 712
Olivera Grbovic-Huezo United States 7 373 1.3× 652 2.7× 84 0.6× 180 1.6× 68 0.7× 8 950
Lauren Schaff United States 11 161 0.6× 280 1.2× 243 1.7× 145 1.3× 111 1.2× 46 966
HuiYong Zhao United States 12 426 1.5× 584 2.5× 249 1.8× 165 1.5× 133 1.5× 18 1.1k
Christopher Ware United States 10 192 0.7× 380 1.6× 71 0.5× 122 1.1× 71 0.8× 11 715

Countries citing papers authored by Alessia Bottos

Since Specialization
Citations

This map shows the geographic impact of Alessia Bottos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessia Bottos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessia Bottos more than expected).

Fields of papers citing papers by Alessia Bottos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessia Bottos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessia Bottos. The network helps show where Alessia Bottos may publish in the future.

Co-authorship network of co-authors of Alessia Bottos

This figure shows the co-authorship network connecting the top 25 collaborators of Alessia Bottos. A scholar is included among the top collaborators of Alessia Bottos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessia Bottos. Alessia Bottos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schmeing, Stephan, Sina Nassiri, Emilio Yángüez, et al.. (2026). Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma. Blood Advances.
2.
Hutchings, Martin, Anna Sureda, Francesc Bosch, et al.. (2025). Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. Journal of Clinical Oncology. 43(36). 3788–3798.
3.
Abramson, Jeremy S., Matthew Ku, Mark Hertzberg, et al.. (2025). Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.. Journal of Clinical Oncology. 43(16_suppl). 7015–7015.
4.
Morschhauser, Franck, Gilles Salles, Yanwen Jiang, et al.. (2025). gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profiles. Leukemia & lymphoma. 66(5). 898–905.
5.
Phillips, Tycel, Matthew J. Matasar, Toby A. Eyre, et al.. (2024). MCL-339 GLOBRYTE: A Phase III, Open-label Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24. S515–S515. 1 indexed citations
6.
7.
Bartlett, Nancy L., Michael Dickinson, Martin Hutchings, et al.. (2024). Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study.. Journal of Clinical Oncology. 42(16_suppl). 7020–7020.
8.
Signori, Chiara, Martina Di Trani, Maria Cristina Pirosa, et al.. (2024). Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy. Blood. 144(Supplement 1). 4356–4356. 1 indexed citations
9.
Lovejoy, Alexander F., et al.. (2024). NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL. Leukemia & lymphoma. 65(5). 618–628. 4 indexed citations
10.
Falchi, Lorenzo, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2023). Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.. Journal of Clinical Oncology. 41(16_suppl). 7550–7550. 11 indexed citations
11.
Dickinson, Michael, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2023). GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY. Hematological Oncology. 41(S2). 144–146. 7 indexed citations
12.
Martelli, Maurizio, Laurie H. Sehn, Umberto Vitolo, et al.. (2022). Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA. Clinical Lymphoma Myeloma & Leukemia. 22(8). e804–e814. 7 indexed citations
13.
14.
Kalberer, Christian P., Martin Stern, Uwe Siegler, et al.. (2020). Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma. Cytotherapy. 23(4). 329–338. 15 indexed citations
15.
Bottos, Alessia, Dagmar Gotthardt, Jason Gill, et al.. (2016). Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nature Communications. 7(1). 12258–12258. 84 indexed citations
16.
Kondo, Shunya, Alessia Bottos, Jeremy C. Allegood, et al.. (2014). Memo Has a Novel Role in S1P Signaling and Crucial for Vascular Development. PLoS ONE. 9(4). e94114–e94114. 13 indexed citations
17.
Samarelli, Anna Valeria, Laura Bizzozero, Tatiana N. Silveira, et al.. (2014). Neuroligin 1 Induces Blood Vessel Maturation by Cooperating with the α6 Integrin. Journal of Biological Chemistry. 289(28). 19466–19476. 28 indexed citations
18.
Bottos, Alessia & Alberto Bardelli. (2013). Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?. Cellular and Molecular Life Sciences. 70(21). 4131–4140. 14 indexed citations
19.
20.
Pignochino, Ymera, Giovanni Grignani, Giuliana Cavalloni, et al.. (2009). Abstract C213: Sorafenib blocks tumor growth, angiogenesis, and metastatic potential in preclinical models of osteosarcoma through the inhibition of ERK1/2, MCL-1, and ezrin pathways. Molecular Cancer Therapeutics. 8(12_Supplement). C213–C213. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fiona Chionh Breakdown of academic impact, for papers by Julie Godet Breakdown of academic impact, for papers by Muayad F. Almahariq Breakdown of academic impact, for papers by Gina Lama Breakdown of academic impact, for papers by Nataliya V. Uboha Breakdown of academic impact, for papers by Yolanda Ruano Breakdown of academic impact, for papers by Olivera Grbovic-Huezo Breakdown of academic impact, for papers by Lauren Schaff Breakdown of academic impact, for papers by HuiYong Zhao Breakdown of academic impact, for papers by Christopher Ware
Rankless by CCL
2026